2022年第25届美国基因与细胞治疗学会年会

2022年第25届美国基因与细胞治疗学会(ASGCT)年会将于2022年5月16日至19日在美国华盛顿举行。ASGCT年会是全球基因和细胞治疗领域规模最大的学术会议，为与会者提供了一个介绍最新基因与细胞疗法的发展以及提出并进行批判性讨论的国际平台。作为全球领先的基因与细胞治疗学会议，ASGCT年会吸引了近3500名来自世界各地的专业人士与会，与会者包括科学家、医生、患者和支持者等等（2021年虚拟会议有近6800余名代表参与）。

美国基因与细胞治疗学会(ASGCT)成立于1996年，是全球最大的专业从事基因和细胞治疗研究的非赢利性医学组织，是世界基因与细胞治疗领域最具权威性与公信力的机构，在全球拥有超过2500名成员。ASGCT宣设有癌症治疗、心血管和遗传委员会等若干个科学委员会。

摘要征集：

• November 16, 2021: Submission opens 摘要投稿开始
• February 2, 2022: Submission closes 摘要投稿截止
• April 11, 2022: Acceptance notifications sent
• April 15, 2022: Abstract withdrawal deadline
• April 18, 2022: Abstracts released to the media
• May 2, 2022: Abstracts released to the public
• May 16-19, 2022: 25th Annual Meeting

点此提交摘要>>>Submit Abstract>>>

Topics

A1 – RNA Virus Vectors
A2 – AAV Vectors – Virology and Vectorology
A3 – AAV Vectors – Preclinical and Proof-of-Concept Studies
A4 – AAV Vectors – Clinical Studies
B – Gene Targeting and Gene Correction (Basic development of novel technologies for genome editing, with or without site-specific endonuclease. Gene targeting projects focused on specific disease applications are strongly encouraged to submit abstracts to the suitable tissue/disease related category.)
C – Oligonucleotide Therapeutics (siRNAs, aptamers, antagomirs, miRNAs, shRNA, antisense, and splice switching oligos, plasmids)
D – Synthetic/Molecular Conjugates and Physical Methods for Delivery of Gene Therapeutics (Including exosomes)
E1 – Metabolic, Storage, Endocrine, Liver and Gastrointestinal Diseases
E2 – Cardiovascular and Pulmonary Diseases
E3 – Neurologic Diseases 
E4 – Ophthalmic and Auditory Diseases
E5 – Musculo-skeletal Diseases
E6 – Cancer – Immunotherapy, Cancer Vaccines
E7 – Cancer – Oncolytic Viruses
E8 – Cancer – Targeted Gene and Cell Therapy
E9 – Hematologic and Immunologic Diseases
F – Immunological Aspects of Gene Therapy and Vaccines (Includes host responses, therapy/prevention of infectious diseases; excludes cancer immunotherapy and cancer vaccines)
G – Cell Therapies (Includes development of somatic, embryonic and induced pluripotent stem cells or other therapeutic cell populations, and issues related to cell expansion or processing)
H1 – Vector Product Engineering, Development, or Manufacturing
H2 – Cell Therapy Product Engineering, Development, and Manufacturing
H3 – Pharmacology/Toxicology Studies or Assay Development
I – Gene & Cell Therapy Trials in Progress

ASGCT2022 注册费：

The same rates apply for in-person and virtual registrants

会议对象: 医生、医院科室主任/副主任、住院医师、医院管理者、医护人员以及从事该领域研究的科学家、研究人员、医药企业代表等等。